Rebound insomnia: duration of use and individual differences

Area of Science:

• Pharmacology
• Sleep Medicine
• Clinical Psychology

Background:

• Rebound insomnia is a potential adverse effect following the discontinuation of sedative-hypnotic medications.
• Understanding the factors influencing rebound insomnia, such as drug duration and individual patient characteristics, is crucial for clinical practice.

Purpose of the Study:

• To investigate the consistency, duration of use, and individual differences in rebound insomnia following triazolam discontinuation.
• To assess the impact of triazolam treatment duration (1, 6, and 12 nights) on the occurrence and intensity of rebound insomnia.

Main Methods:

• A double-blind, Latin square design was employed with 11 healthy male participants (aged 20-30) with normal sleep.
• Participants received triazolam (0.50 mg) for 1, 6, and 12 nights, and placebo for 12 nights, followed by two placebo discontinuation nights.
• Sleep was assessed using subjective and polysomnographic criteria.

Main Results:

• Triazolam improved sleep compared to placebo, with no difference between the first and last nights of treatment.
• Upon discontinuation after active drug treatment, sleep efficiency decreased compared to placebo.
• The duration of triazolam administration did not influence the likelihood or intensity of rebound insomnia.

Conclusions:

• Rebound insomnia can occur after triazolam discontinuation, characterized by reduced sleep efficiency.
• Individual differences in baseline sleep quality and drug effect appear to be more significant predictors of rebound insomnia than treatment duration.
• Further research into personalized approaches for managing hypnotic discontinuation is warranted.